JPWO2019195164A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019195164A5 JPWO2019195164A5 JP2020553619A JP2020553619A JPWO2019195164A5 JP WO2019195164 A5 JPWO2019195164 A5 JP WO2019195164A5 JP 2020553619 A JP2020553619 A JP 2020553619A JP 2020553619 A JP2020553619 A JP 2020553619A JP WO2019195164 A5 JPWO2019195164 A5 JP WO2019195164A5
- Authority
- JP
- Japan
- Prior art keywords
- lactic acid
- oligo
- gemcitabine
- cancer
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 78
- 229960005277 gemcitabine Drugs 0.000 claims description 39
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 34
- 229940022769 d- lactic acid Drugs 0.000 claims description 33
- 235000014655 lactic acid Nutrition 0.000 claims description 17
- 239000004310 lactic acid Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 13
- 229920001577 copolymer Polymers 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 239000000693 micelle Substances 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 201000009036 biliary tract cancer Diseases 0.000 claims description 4
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 206010004593 Bile duct cancer Diseases 0.000 claims description 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 3
- 201000003076 Angiosarcoma Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000007822 coupling agent Substances 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 231100000636 lethal dose Toxicity 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002253 acid Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862651365P | 2018-04-02 | 2018-04-02 | |
| US62/651,365 | 2018-04-02 | ||
| PCT/US2019/025174 WO2019195164A1 (en) | 2018-04-02 | 2019-04-01 | Stereocomplex of oligolactic acid conjugates in micelles for improved physical stability and enhanced antitumor efficacy |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021520344A JP2021520344A (ja) | 2021-08-19 |
| JPWO2019195164A5 true JPWO2019195164A5 (https=) | 2022-04-04 |
| JP2021520344A5 JP2021520344A5 (https=) | 2022-04-04 |
| JP7495352B2 JP7495352B2 (ja) | 2024-06-04 |
Family
ID=66175512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020553619A Active JP7495352B2 (ja) | 2018-04-02 | 2019-04-01 | 物理的安定性の向上および抗腫瘍効果の増強のためのミセルにおけるオリゴ乳酸コンジュゲートのステレオコンプレックス |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20210128736A1 (https=) |
| JP (1) | JP7495352B2 (https=) |
| KR (1) | KR20200139737A (https=) |
| CN (1) | CN112105390A (https=) |
| CA (1) | CA3095788A1 (https=) |
| WO (1) | WO2019195164A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110652595B (zh) * | 2019-10-21 | 2022-11-29 | 南通大学附属医院 | 一种聚亮氨酸-聚天冬氨酸嵌段共聚物立构复合载药胶束及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8416234D0 (en) | 1984-06-26 | 1984-08-01 | Ici Plc | Biodegradable amphipathic copolymers |
| KR0180334B1 (ko) | 1995-09-21 | 1999-03-20 | 김윤 | 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법 |
| JP5048690B2 (ja) * | 2006-03-08 | 2012-10-17 | クローズ | 特に種子発芽および植物発生のための遅延性効果の農業処理剤 |
| US8668919B2 (en) * | 2009-03-03 | 2014-03-11 | Abbott Cardiovascular Systems Inc. | Polymer for creating hemocompatible surface |
| CN103599073A (zh) * | 2013-11-15 | 2014-02-26 | 无锡中科光远生物材料有限公司 | 一种负载有靶向抗癌药物的plga微米颗粒的制备方法 |
| CN104961786B (zh) * | 2015-06-05 | 2018-09-25 | 苏州大学 | 基于吉西他滨结构的前体药物及其应用 |
| ES2804251T3 (es) | 2016-03-14 | 2021-02-05 | Wisconsin Alumni Res Found | Conjugados y micelas de ácido oligoláctico con eficacia anticáncer mejorada |
| WO2017201407A1 (en) * | 2016-05-20 | 2017-11-23 | Massachusetts Institute Of Technology | Hydrogel particle of cystamine cross-linked dextran aldehyde containing imine conjugated doxorubicin and rgd peptide for chemotherapy |
-
2019
- 2019-04-01 US US17/044,189 patent/US20210128736A1/en not_active Abandoned
- 2019-04-01 WO PCT/US2019/025174 patent/WO2019195164A1/en not_active Ceased
- 2019-04-01 KR KR1020207031253A patent/KR20200139737A/ko not_active Ceased
- 2019-04-01 CA CA3095788A patent/CA3095788A1/en active Pending
- 2019-04-01 CN CN201980031778.XA patent/CN112105390A/zh active Pending
- 2019-04-01 JP JP2020553619A patent/JP7495352B2/ja active Active
-
2024
- 2024-01-26 US US18/424,697 patent/US20240207416A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102948775B1 (ko) | 치료 덴드리머 | |
| JP5544357B2 (ja) | 水酸基を有する生理活性物質の高分子結合体 | |
| KR102811484B1 (ko) | 치료 덴드리머 | |
| US20160166693A1 (en) | Radiation enhanced macromolecular delivery of therapeutic agents for chemotherapy | |
| JP7359449B2 (ja) | オーリスタチンｅ誘導体のアルブミン結合プロドラッグ | |
| CN102264396A (zh) | Hpma-多西他赛或吉西他滨缀合物及其用途 | |
| JP6223995B2 (ja) | カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 | |
| CN103800915A (zh) | 一种靶向整合素受体的联合载药胶束及其制备方法 | |
| JP5613679B2 (ja) | 腹腔内投与用の抗がん剤含有ブロック共重合体、ミセル調製物及びそれを有効成分とする癌治療薬 | |
| JP2021520344A5 (https=) | ||
| JPWO2019195164A5 (https=) | ||
| EP4034169B1 (en) | Therapeutic dendrimer | |
| CN111201018A (zh) | 用于治疗与改变的tca循环代谢相关的病状的组合物和方法 | |
| CN104981245B (zh) | 无副作用的抗癌剂 | |
| HK40040808B (en) | Albumin-binding prodrugs of auristatin e derivatives | |
| HK40040808A (en) | Albumin-binding prodrugs of auristatin e derivatives |